Sales decline slows in third quarter, AstraZeneca says brighter future ahead

9 November 2017

The UK’s AstraZeneca (LSE: AZN) has released third quarter 2017 results showing revenue of $6.2 billion, a 9% rise from the same period last year, amid continuing generic competition around big sellers such as cholesterol pill Crestor (rosuvastatin).

Following generally accepted accounting principles (GAAP), profit for the quarter was $1.1 billion, which equates to earnings per share (EPS) of $1.12, a decline of around 15%.

AstraZeneca’s share price, which since August has steadily recovered to pre- MYSTIC levels, is off slightly in London this afternoon, as the company revealed sales were still in decline, although at a slower rate than in previous periods.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK